AI Article Synopsis
- - Dealing with patients who have both multiple sclerosis (MS) and inflammatory rheumatic disorders (IRDs) is common for rheumatologists, due to the statistical connection between conditions like spondyloarthritis (SpA) and MS.
- - Although TNF inhibitors (TNFi) have been seen as a contraindication for patients with pre-existing demyelinating diseases based on past research, new epidemiological studies suggest that TNFi may not actually trigger MS.
- - The review highlights the relationship between MS and IRDs, discusses the effects of disease-modifying anti-rheumatic drugs (DMARDs) on MS, particularly focusing on TNFi, and notes the lack of clear guidelines for treating patients with both conditions.
Article Abstract
Dealing with patients with both multiple sclerosis (MS) and inflammatory rheumatic disorders (IRDs) is not uncommon for a rheumatologist, as there is a statistical association between SpA and MS. As several CNS demyelinating events have been reported in patients treated with TNF inhibitor (TNFi), the pre-existing demyelinating disease was considered a contraindication for TNFi. However, this contraindication is mainly based on a randomized controlled trial in MS and not on large epidemiological studies. According to the last epidemiological studies, TNFi might not be an inducer of MS. Moreover, there are no clear recommendations on the use of the other DMARDs in patients suffering from an IRD and MS. In this review, we summarize the link between MS and IRDs and the impact of DMARDs on MS, especially TNFi. We also look at the impact of disease-modifying drugs for adults with MS and IRDs.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/rheumatology/keac665 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!